Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases

April 1, 2026 updated by: Prof. Dr. Pia Vécsei-Marlovits, Hospital Hietzing
The study compares the perceived treatment burden in patients undergoing intravitreal anti-VEGF treatment for either wet age related macular degeneration, macular edema after retinal vein occlusions or diabetic macular edema. This study is the first to the investigator's knowledge to compare treatment burden between all three patient groups, which also differ in age and socioeconomic circumstances. The results are of interest to all ophthalmologists who prescribe anti-VEGF treatments, as they show factors which can influence patient adherence und thus the efficacy of said therapies.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

393

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Vienna, Austria, 1130
        • Hietzing Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

393 patients (305 with nAMD, 55 with CME and 33 with DME)

Description

Inclusion Criteria:

  • undergone a minimum of 5 IVT's and had visited the retina clinic for at least 6 months

Exclusion Criteria:

  • eye surgery in the preceding six months
  • notable cognitive impairment, such as dementia
  • age <18 years

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
AMD
Patients with AMD receiving anti-VEGF treatment
DME
Patients with DME receiving anti-VEGF treatment
RVO
Patients with RVO receiving anti-VEGF treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severitiy of subjective treatment burden due to intravitreal anti-VEGF therapy assessed by questionnaire
Time Frame: From May 2023 to April 2024
The questionnaire was designed on the basis of the Longitudinal assessment of Adherence Factors to Intravitreal (anti-VEGF) Therapy (LAF-IVT) questionnaire. Patients were interviewed about their perceived treatment burden, their socioeconomic status, and demographic details. Different aspects of treatment burden were graden by the patients as "no", "little", "moderate", "great" or "extreme buden".
From May 2023 to April 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Hietzing

Collaborators

Scientific fund of the City of Vienna

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2023

Primary Completion (Actual)

April 30, 2024

Study Completion (Actual)

April 30, 2024

Study Registration Dates

First Submitted

March 26, 2026

First Submitted That Met QC Criteria

April 1, 2026

First Posted (Actual)

April 7, 2026

Study Record Updates

Last Update Posted (Actual)

April 7, 2026

Last Update Submitted That Met QC Criteria

April 1, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EK 22-198-VK

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Age Related Macular Degeneration (ARMD)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe